|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
58
|
|
pubmed:dateCreated |
2004-7-8
|
|
pubmed:abstractText |
New perspectives in the treatment of advanced hepatocellular carcinomas have recently been inaugurated with the application of hydroxymethylglutaryl coenzyme A reductase inhibitors i.e. pravastatin, the somatostatin analogue octreotide, or the cytidine analogue gemcitabine. The present study aimed to evaluate these substances in patients with progressive tumor growth.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0172-6390
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1099-103
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15239254-Aged,
pubmed-meshheading:15239254-Antimetabolites, Antineoplastic,
pubmed-meshheading:15239254-Antineoplastic Agents, Hormonal,
pubmed-meshheading:15239254-Carcinoma, Hepatocellular,
pubmed-meshheading:15239254-Deoxycytidine,
pubmed-meshheading:15239254-Female,
pubmed-meshheading:15239254-Humans,
pubmed-meshheading:15239254-Liver Neoplasms,
pubmed-meshheading:15239254-Male,
pubmed-meshheading:15239254-Middle Aged,
pubmed-meshheading:15239254-Octreotide,
pubmed-meshheading:15239254-Pravastatin,
pubmed-meshheading:15239254-Survival Analysis
|
|
pubmed:articleTitle |
Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation.
|
|
pubmed:affiliation |
II. Department of Internal Medicine, Technical University of Munich, Klinikum Rechts der Isar, Munich, Germany. christian.lersch@lrz.tum.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|
